Stefania Ciolli

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.

Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.

Journal: American journal of hematology

Published: January 20, 2022

Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.

Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.

Journal: American journal of hematology

Published: November 24, 2021

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Journal: Cancers

Published: May 16, 2021

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Journal: Blood advances

Published: March 22, 2021

Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.

Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.

Journal: British journal of haematology

Published: August 01, 2019

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.

Journal: European journal of haematology

Published: July 25, 2018

Eosinophilic dermatosis of hematologic malignancy: A retrospective cohort of 37 patients from an Italian center.

Eosinophilic dermatosis of hematologic malignancy: A retrospective cohort of 37 patients from an Italian center.

Journal: Journal of the American Academy of Dermatology

Published: May 10, 2018

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Journal: Haematologica

Published: February 06, 2018

CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia.

CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia.

Journal: Hematological oncology

Published: December 18, 2017

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.

Journal: Leukemia

Published: December 17, 2017

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.

Journal: Haematologica

Published: June 10, 2017

Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.

Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 12, 2016

Showing 1-12 of 18

Last Updated: 09/26/2026